A SIMPLE KEY FOR NINTEDANIB UNVEILED

There have been no clinically substantial variations while in the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when applied concomitantly with finerenone. Several doses of forty mg finerenone at the time-each day had no clinically suitable impact on AUC or Cmax in the BCRP and OATP substrate rosuvastat